Patents by Inventor Brian Metcalf

Brian Metcalf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
    Publication number: 20150344472
    Abstract: Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Application
    Filed: March 18, 2015
    Publication date: December 3, 2015
    Inventors: Brian Metcalf, Chihyuan Chuang, Jeffrey Warrington, Kumar Paulvannan, Matthew P. Jacobson, Lan Hua, Bradley Morgan
  • SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
    Publication number: 20150344483
    Abstract: Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Application
    Filed: March 18, 2015
    Publication date: December 3, 2015
    Inventors: Brian Metcalf, Chihyuan Chuang, Jeffrey Warrington, Kumar Paulvannan, Matthew P. Jacobson, Lan Hua, Bradley Morgan
  • Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
    Patent number: 9018210
    Abstract: Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: April 28, 2015
    Assignees: Global Blood Therapeutics, Inc., Cytokinetics, Inc., The Regents of the University of California
    Inventors: Brian Metcalf, Chihyuan Chuang
  • Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
    Patent number: 9012450
    Abstract: Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: April 21, 2015
    Assignees: Global Blood Therapeutics, Inc., Cytokinetics, Inc., The Regents of the University of California
    Inventors: Brian Metcalf, Chihyuan Chuang, Jeffrey Warrington, Kumar Paulvannan, Matthew P. Jacobson, Lan Hua, Bradley Morgan
  • PURINONE DERIVATIVES AS HM74A AGONISTS
    Publication number: 20140371216
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Application
    Filed: April 18, 2014
    Publication date: December 18, 2014
    Applicant: Incyte Corporation
    Inventors: Changsheng Zheng, Chu-Biao Xue, Ganfeng Cao, Michael Xia, Anlai Wang, Hai Fen Ye, Brian Metcalf
  • Purinone derivatives as HM74A agonists
    Patent number: 8703783
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: April 22, 2014
    Assignee: Incyte Corporation
    Inventors: Changsheng Zheng, Chu-Biao Xue, Ganfeng Cao, Michael Xia, Anlai Wang, Hai Fen Ye, Brian Metcalf
  • AZA spiro alkane derivatives as inhibitors of metalloproteases
    Patent number: 8637497
    Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: January 28, 2014
    Assignee: Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Fenglei Zhang, Brian Metcalf
  • IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS
    Publication number: 20130324515
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Application
    Filed: May 16, 2013
    Publication date: December 5, 2013
    Applicant: INCYTE CORPORATION
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Din-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Lactam compounds and their use as pharmaceuticals
    Patent number: 8563570
    Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: October 22, 2013
    Assignee: Incyte Corporation
    Inventors: Wenqing Yao, Chunhong He, David M. Burns, Jincong Zhuo, Meizhong Xu, Colin Zhang, Ding-Quan Qian, Brian Metcalf
  • Imidazotriazines and imidazopyrimidines as kinase inhibitors
    Patent number: 8461330
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: June 11, 2013
    Assignee: Incyte Corporation
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20120122858
    Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    Type: Application
    Filed: January 20, 2012
    Publication date: May 17, 2012
    Applicant: Incyte Corporation
    Inventors: Wenqing Yao, Chunhong He, David M. Burns, Jincong Zhuo, Meizhong Xu, Colin Zhang, Ding-Quan Qian, Brian Metcalf
  • Purinone Derivatives as HM74A Agonists
    Publication number: 20120035172
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Application
    Filed: October 17, 2011
    Publication date: February 9, 2012
    Applicant: INCYTE CORPORATION
    Inventors: Changsheng Zheng, Chu-Biao Xue, Ganfeng Cao, Michael Xia, Anlai Wang, Hai Fen Ye, Brian Metcalf
  • Lactam compounds and their use as pharmaceuticals
    Patent number: 8110581
    Abstract: The present invention relates to inhibitors of 11-?hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-?hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: February 7, 2012
    Assignee: Incyte Corporation
    Inventors: Wenqing Yao, Chunhong He, David M. Burns, Jincong Zhuo, Meizhong Xu, Colin Zhang, Ding-Quan Qian, Brian Metcalf
  • AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES
    Publication number: 20110288068
    Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    Type: Application
    Filed: July 18, 2011
    Publication date: November 24, 2011
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Fenglei Zhang, Brian Metcalf
  • Aza spiro alkane derivatives as inhibitors of metalloproteases
    Patent number: 8039471
    Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: October 18, 2011
    Assignee: Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Fenglei Zhang, Brian Metcalf
  • Purinone derivatives as HM74A agonists
    Patent number: 8039478
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: October 18, 2011
    Assignee: Incyte Corporation
    Inventors: Changsheng Zheng, Chu-Biao Xue, Ganfeng Cao, Michael Xia, Anlai Wang, Hai Fen Ye, Brian Metcalf
  • IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS
    Publication number: 20110136781
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Application
    Filed: June 10, 2010
    Publication date: June 9, 2011
    Applicant: Incyte Corporation
    Inventors: Jincong ZHUO, Meizhong XU, Chunhong HE, Colin ZHANG, Ding-Quan QIAN, David M. BURNS, Yun-Long LI, Brian METCALF, Wenqing YAO
  • Purinone derivatives as HM74A agonists
    Patent number: 7902205
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: March 8, 2011
    Assignee: Incyte Corporation
    Inventors: Chu-Biao Xue, Brian Metcalf, Anlai Wang, Changsheng Zheng, Ganfeng Cao, Ke Zhang
  • Purinone derivatives as HM74A agonists
    Patent number: 7863285
    Abstract: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: January 4, 2011
    Assignee: Incyte Corporation
    Inventors: Chu-Biao Xue, Brian Metcalf, Anlai Wang, Changsheng Zheng, Ganfeng Cao, Ke Zhang
  • Imidazotriazines and imidazopyrimidines as kinase inhibitors
    Patent number: 7767675
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: August 3, 2010
    Assignee: Incyte Corporation
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, Brian Metcalf, Wenqing Yao